Browse SETD2

Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome
Domain PF00856 SET domain
PF08236 SRI (Set2 Rpb1 interacting) domain
PF00397 WW domain
Function

Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate (PubMed:16118227, PubMed:19141475, PubMed:21526191, PubMed:21792193, PubMed:23043551, PubMed:27474439). Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation (By similarity). Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A (PubMed:23325844). Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction (PubMed:23622243). Required for DNA double-strand break repair in response to DNA damage: acts by mediating formation of H3K36me3, promoting recruitment of RAD51 and DNA repair via homologous recombination (HR) (PubMed:24843002). Acts as a tumor suppressor (PubMed:24509477). H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A (PubMed:27317772). H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase (PubMed:21792193). Required during angiogenesis (By similarity). Required for endoderm development by promoting embryonic stem cell differentiation toward endoderm: acts by mediating formation of H3K36me3 in distal promoter regions of FGFR3, leading to regulate transcription initiation of FGFR3 (By similarity). In addition to histones, also mediates methylation of other proteins, such as tubulins and STAT1 (PubMed:27518565, PubMed:28753426). Trimethylates 'Lys-40' of alpha-tubulins such as TUBA1B (alpha-TubK40me3); alpha-TubK40me3 is required for normal mitosis and cytokinesis and may be a specific tag in cytoskeletal remodeling (PubMed:27518565). Involved in interferon-alpha-induced antiviral defense by mediating both monomethylation of STAT1 at 'Lys-525' and catalyzing H3K36me3 on promoters of some interferon-stimulated genes (ISGs) to activate gene transcription (PubMed:28753426). ; FUNCTION: (Microbial infection) Recruited to the promoters of adenovirus 12 E1A gene in case of infection, possibly leading to regulate its expression.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0001701 in utero embryonic development
GO:0001763 morphogenesis of a branching structure
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0006298 mismatch repair
GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006406 mRNA export from nucleus
GO:0006479 protein methylation
GO:0006913 nucleocytoplasmic transport
GO:0007498 mesoderm development
GO:0007507 heart development
GO:0008213 protein alkylation
GO:0010452 histone H3-K36 methylation
GO:0010793 regulation of mRNA export from nucleus
GO:0014020 primary neural tube formation
GO:0015931 nucleobase-containing compound transport
GO:0016331 morphogenesis of embryonic epithelium
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018023 peptidyl-lysine trimethylation
GO:0018027 peptidyl-lysine dimethylation
GO:0018205 peptidyl-lysine modification
GO:0021915 neural tube development
GO:0030900 forebrain development
GO:0032239 regulation of nucleobase-containing compound transport
GO:0032259 methylation
GO:0032386 regulation of intracellular transport
GO:0034728 nucleosome organization
GO:0034968 histone lysine methylation
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035441 cell migration involved in vasculogenesis
GO:0043414 macromolecule methylation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046831 regulation of RNA export from nucleus
GO:0048332 mesoderm morphogenesis
GO:0048514 blood vessel morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0051028 mRNA transport
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
GO:0060039 pericardium development
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060669 embryonic placenta morphogenesis
GO:0060976 coronary vasculature development
GO:0060977 coronary vasculature morphogenesis
GO:0061458 reproductive system development
GO:0071166 ribonucleoprotein complex localization
GO:0071426 ribonucleoprotein complex export from nucleus
GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus
GO:0071824 protein-DNA complex subunit organization
GO:0072175 epithelial tube formation
GO:0097198 histone H3-K36 trimethylation
GO:0097676 histone H3-K36 dimethylation
GO:1904888 cranial skeletal system development
GO:2000197 regulation of ribonucleoprotein complex localization
Molecular Function GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
GO:0046975 histone methyltransferase activity (H3-K36 specific)
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00310 Lysine degradation
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214841: PKMTs methylate histone lysines
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SETD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SETD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: 2.72; FDR: 0.000381 Sensitive to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SETD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0510.808
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.020.988
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0720.942
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0880.778
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.110.967
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3410.921
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0680.848
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0740.966
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0670.972
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5380.601
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4450.3
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0110.828
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SETD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.88.56.30.453
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171911.87.20.672
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.818.212.60.649
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111336.438.5-2.11
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6133.3033.31
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5124041.7-1.71
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SETD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SETD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SETD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SETD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SETD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SETD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSETD2
NameSET domain containing 2
Aliases HYPB; HIF-1; KIAA1732; FLJ23184; KMT3A; HBP231; HSPC069; SET2; p231HBP; huntingtin yeast partner B; huntingt ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SETD2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.